Shots:
- The US FDA has approved Enzeevu, biosimilar version of Eylea (aflibercept), 2mg vial kit & pre-filled syringe for intravitreal injection for enhanced & sustained visual acuity among neovascular age-related macular degeneration (nAMD) patients
- Approval was supported by the analytical & preclinical in vitro results plus data from Mylight trial, assessing Enzeevu (aflibercept-abzv) vs Eylea in nAMD patients (n=485) for 52wks., that demonstrated similar efficacy, safety & immunogenicity b/w Enzeevu & Eylea
- Enzeevu, a recombinant fusion protein, inhibits abnormal vessel growth by binding with VEGF-A & PlGF. It is injected into the eye among nAMD patients for enhancing visual acuity & slowing disease progression
Ref: Globenewswire| Image: Sandoz| Press Release
Related News:- Lupin Reports the P-III Study Completion of LUBT010 (Biosimilar, Lucentis) for Neovascular Age-related Macular Degeneration
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
